Ipsen to terminate Irosustat development in monotherapy
Irosustat is an orally available irreversible steroid sulfatase (STS) inhibitor. According to futility analysis, the trial will not meet the primary endpoint and the superiority will not be
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Semuloparin is an investigational selectively engineered Ultra-LMWH (low molecular weight heparin) with enriched anti-thrombin binding sites. Semuloparin reduced the risk of this type of blood clots without increasing